Minerva Neurosciences Elects Jeryl Hilleman to Board of Directors
July 17 2018 - 4:05PM
WALTHAM, Mass., July 17, 2018 (GLOBE NEWSWIRE) --
Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage
biopharmaceutical company focused on the development of therapies
to treat central nervous system (CNS) disorders, today announced
the election of Jeryl Hilleman to the Board of Directors of the
Company.
"Jeri brings a broad life sciences background to
Minerva that includes high growth commercial biopharma, med-tech
and data science companies," said William F. Doyle, Lead
Independent Director of Minerva. "Her track record of
delivering strategic and financial growth through execution,
strategic partnering and multiple acquisitions will serve Minerva
well as the Company completes five ongoing late-stage clinical
trials with roluperidone, seltorexant and MIN-117."
Ms. Hilleman is presently Chief
Financial Officer of Intersect ENT (NASDAQ:XENT), a medical device
company with commercial products for the treatment of chronic
sinusitis. Previously, she served as CFO of several public
companies, including Amyris, a renewable products company, Symyx
Technologies (acquired), which provided research services, software
and instrumentation, Ocera (acquired), a biopharma company, and
Cytel (acquired), an immunotherapy company. Ms. Hilleman served as
a member of the Board of Directors and Chair of the Audit Committee
of Xenoport, Inc. (acquired), a commercial biopharma company, for
over ten years, from IPO through acquisition. Ms. Hilleman holds an
A.B. from Brown University and an M.B.A. from the Wharton Graduate
School of Business. She is a member of the 1999 class of Henry
Crown Fellows and the Aspen Global Leadership Network at the Aspen
Institute.
About Minerva
Neurosciences:
Minerva Neurosciences, Inc. is a clinical-stage
biopharmaceutical company focused on the development and
commercialization of a portfolio of product candidates to treat CNS
diseases. Minerva's proprietary compounds include:
roluperidone (MIN-101), in clinical development for schizophrenia;
MIN-117, in clinical development for major depressive disorder
(MDD); seltorexant (MIN-202 or JNJ-42847922), in clinical
development for insomnia and MDD; and MIN-301, in pre-clinical
development for Parkinson's disease. Minerva's common stock
is listed on the NASDAQ Global Market under the symbol
"NERV." For more information, please
visit www.minervaneurosciences.com.
Forward-Looking Safe Harbor Statement
This press release contains
forward-looking statements which are subject to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995,
as amended. Forward-looking statements are statements that
are not historical facts, reflect management's expectations as of
the date of this press release, and involve certain risks and
uncertainties. Forward-looking statements include statements
herein with respect to Ms. Hilleman's positive impact on us,
including as we proceed through clinical trials. These
forward-looking statements are based on our current expectations
and may differ materially from actual results due to a variety of
factors including, without limitation, Ms. Hilleman's and our
ability to perform as expected. These and other potential
risks and uncertainties that could cause actual results to differ
from the results predicted are more fully detailed under the
caption "Risk Factors" in our filings with the Securities and
Exchange Commission, including our Quarterly Report on Form 10-Q
for the quarter ended March 31, 2018, filed with
the Securities and Exchange Commission on May 3, 2018.
Copies of reports filed with the SEC are posted on our
website at www.minervaneurosciences.com. The
forward-looking statements in this press release are based on
information available to us as of the date hereof, and we disclaim
any obligation to update any forward-looking statements, except as
required by law.
Contact:
William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Minerva Neurosciences, Inc. via Globenewswire
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Apr 2024 to May 2024
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From May 2023 to May 2024